Iovance rises as 2026 revenue outlook tops analyst consensus

Iovance Biotherapeutics (IOVA) raised its full-year 2026 revenue guidance to $410M-$420M, up from the previous range of $350M-$370M. The new guidance is above the $402.8M analyst consensus.

The company said stronger U.S. demand for Amtagvi and Proleukin is driving the higher outlook.

“Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint,” said Frederick Vogt, Ph.D., J.D., interim president and CEO.

Iovance (IOVA) reported $99.3M in Q2 2026 product revenue and expects to report Q3 results in early November. The stock price climbed about 6% on Tuesday during pre-market hours of trading.